Diaceutics’ (DXRX) “Buy” Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Diaceutics (LON:DXRX) in a research note published on Tuesday morning, Marketbeat.com reports. Canaccord Genuity Group currently has a GBX 160 ($2.00) price objective on the stock.

Separately, Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 160 ($2.00) target price on shares of Diaceutics in a research note on Tuesday.

Diaceutics Stock Up 0.8 %

Shares of Diaceutics stock opened at GBX 125 ($1.56) on Tuesday. Diaceutics has a 1 year low of GBX 84.50 ($1.06) and a 1 year high of GBX 136 ($1.70). The company has a debt-to-equity ratio of 2.93, a current ratio of 4.85 and a quick ratio of 9.92. The company has a 50-day moving average of GBX 121.85 and a 200 day moving average of GBX 126.16. The firm has a market cap of £105.59 million, a price-to-earnings ratio of -4,166.67 and a beta of 0.58.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.